Skip to main content
. 2023 Feb 23;12(2):266–276. doi: 10.21037/tlcr-22-556

Figure 1.

Figure 1

Progression-free survival (A) and overall survival (B) of patients (intention-to-treat population) with advanced non-squamous NSCLC treated with the association of pembrolizumab plus chemotherapy. NSCLC, non-small cell lung cancer.